INVAInnoviva, Inc.

$1B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$331M-15.4% YoY

Gross Profit

$318M95.8% margin

Operating Income

-$37M-11.2% margin

Net Income

$214M64.6% margin

EPS (Diluted)

$2.37

Cash Flow

Operating Cash Flow

$202M

Free Cash Flow

$202M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$666M

Stockholders' Equity

$566M

Cash & Equivalents

$291M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$331M	$392M	-15.4%
Gross Profit	$318M	$392M	-19.0%
Operating Income	-$37M	$375M	-109.8%
Net Income	$214M	$266M	-19.5%

INVA FY 2022 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena